| Q43830000 | A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer |
| Q38210345 | Advances in managing hepatocellular carcinoma |
| Q84418900 | Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus |
| Q54241755 | Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. |
| Q33633431 | Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials |
| Q37631567 | Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay |
| Q37388064 | Discovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors |
| Q53239742 | Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. |
| Q33400952 | First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study |
| Q46788978 | Human mammary microenvironment better regulates the biology of human breast cancer in humanized mouse model |
| Q54493173 | Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. |
| Q36941168 | Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice |
| Q36629386 | Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A |
| Q44345560 | KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, induces intrauterine growth restriction in mice |
| Q38190359 | Lymphangiogenesis and lymphatic vessel remodelling in cancer |
| Q38196544 | Lymphangiosarcoma of the scalp. |
| Q35184195 | Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib |
| Q34774917 | Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth |
| Q28082461 | Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy |
| Q89976160 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer |
| Q38864758 | Myeloid-derived suppressor cells as effectors of immune suppression in cancer. |
| Q39331381 | Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. |
| Q36137696 | Notch signaling in developmental and tumor angiogenesis |
| Q38026529 | Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. |
| Q86445750 | Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer |
| Q33403848 | Phase II open-label study of sunitinib in patients with advanced breast cancer |
| Q35958869 | Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer |
| Q28080262 | Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy |
| Q36874976 | Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort |
| Q35114038 | Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study |
| Q35993110 | Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. |
| Q54965977 | Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis. |
| Q55265921 | Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. |
| Q37516448 | The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment |
| Q38917878 | The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors |
| Q28076945 | The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development |
| Q38689578 | The lymphatic system and pancreatic cancer |
| Q36589860 | The role of the VEGF-C/VEGFRs axis in tumor progression and therapy |
| Q36808641 | Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions. |
| Q38833891 | Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges |
| Q34674541 | VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. |
Search more.